Consensus practice guidelines for bisphosphonate-associated osteonecrosis of the jaw.
Kolling Institute, Royal North Shore Hospital, University of Sydney, Sydney, Australia.Nature Clinical Practice Rheumatology (impact factor: 5.85). 12/2008; 5(1):6-7. DOI:10.1038/ncprheum0960
[show abstract] [hide abstract]
ABSTRACT: Bisphosphonates are a common treatment for osteoporosis. Osteonecrosis of the jaw has been associated with the use of bisphosphonates, usually when they have been used parenterally to treat malignancies. Cases associated with oral bisphosphonate as a treatment for osteoporosis are less frequent. We describe two patients exhibiting the clinical manifestations of bisphosphonate-associated osteonecrosis of the jaw. A brief review of the literature on the incidence, possible risk factors, and practice guidelines is also presented.Hong Kong medical journal = Xianggang yi xue za zhi / Hong Kong Academy of Medicine 04/2010; 16(2):145-8.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.